<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096496</url>
  </required_header>
  <id_info>
    <org_study_id>QoL-APL0816</org_study_id>
    <nct_id>NCT03096496</nct_id>
  </id_info>
  <brief_title>Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy</brief_title>
  <official_title>Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective and international observational study run by the GIMEMA. All data will
      be centrally collected and analyzed at the GIMEMA Data Center in Rome (Italy). Patients
      reported outcomes will be collected using internationally validated questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To examine long-term differences in health outcomes after treatment end.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>Indicated by selected key-QoL outcomes, between APL patients treated with ATRA plus chemotherapy versus patients treated with ATRA plus ATO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine long-term differences in health outcomes after treatment end indicated by all QoL outcomes not considered in primary objectives, between APL patients treated with ATRA plus chemotherapy versus patients treated with ATRA plus ATO.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>(including the functional status and symptomatology).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate clinical, laboratory, socio-demographic and QoL factors predicting long-term health/QoL outcomes of APL patients after treatment end.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>(as reported at 3rd consolidation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the long-term QoL profile, after treatment end, of APL patients treated with ATRA- chemotherapy and ATRA-ATO with that of their peers in the general population.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>Compared with the general population (without cancer).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare the cumulative incidence and types of physician-reported late adverse effects (e.g. cardiac function) and secondary cancer, between randomized treatment groups.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>(ATRA plus chemotherapy versus ATRA plus ATO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess and compare the prevalence of long-term patient-reported comorbidities and symptoms, after treatment end, between randomized treatment groups.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>(ATRA plus chemotherapy versus ATRA plus ATO).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess long-term QoL patterns over time of long-term APL survivors.</measure>
    <time_frame>Two years after study entry.</time_frame>
    <description>After treatment end, overall and by treatment group.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>GIMEMA APL0406 patients</arm_group_label>
    <description>APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QoL questionnaires</intervention_name>
    <description>Quality of life questionnaires</description>
    <arm_group_label>GIMEMA APL0406 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients previously enrolled in a phase III randomized controlled trial that compared the
        efficacy and toxicity of standard ATRA plus chemotherapy versus ATRA plus ATO in
        low-intermediate risk APL patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  APL survivors enrolled in GIMEMA APL0406 clinical trial and in first molecular CR
             after third consolidation treatment

          -  Written informed consent.

        Exclusion Criteria:

          -  APL patients previously enrolled in GIMEMA APL0406 trial who cannot be reached or who
             are lost to follow-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabio Efficace</last_name>
    <role>Study Chair</role>
    <affiliation>GIMEMA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesca Tartaglia</last_name>
    <phone>+39 06.70390521</phone>
    <email>f.tartaglia@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabio Efficace</last_name>
    <phone>+39 06.70390521</phone>
    <email>f.efficace@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UOC Ematologia e Terapia Cellulare - Ospedale C. e G. Mazzoni di Ascoli Piceno</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catia Bigazzi</last_name>
    </contact>
    <investigator>
      <last_name>Catia Bigazzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Borlenghi</last_name>
    </contact>
    <investigator>
      <last_name>Erika Borlenghi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mara Cecconi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze MEdiche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cuneo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Formigaro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU - Policlinico G. Martino Messina Medicine Specialistiche e Oncologia Medica - UOC Ematologia</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Musolino</last_name>
    </contact>
    <investigator>
      <last_name>Caterina Musolino</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Demetrio Gerace</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Trapianti di Midollo - IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostino CORTELEZZI, Pr.</last_name>
    </contact>
    <investigator>
      <last_name>Agostino CORTELEZZI, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora Ferretti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia - Padiglione Marcora 2do piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agostino Cortelezzi</last_name>
    </contact>
    <investigator>
      <last_name>Agostino Cortelezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia e Trapiano di Midollo - Ist. Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Ciceri</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Gucciari</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Luppi</last_name>
    </contact>
    <investigator>
      <last_name>Mario Luppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Forghieri</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Medicina Interna a indirizzo ematologico</name>
      <address>
        <city>Orbassano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelo Guerrasio</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Guerrasio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia -plesso ospedaliero &quot;A. Tortora&quot; di Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catello Califano</last_name>
    </contact>
    <investigator>
      <last_name>Catello Califano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Flavia Rivellini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti &quot;Villa Sofia-Cervello&quot;</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Fabbiano</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Fabbiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosaria Felice</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Zappasodi, Dr.</last_name>
      <email>p.zappasodi@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Patrizia Zappasodi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele Annino, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica</last_name>
    </contact>
    <investigator>
      <last_name>Simona Sica</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federica Sorà</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavila, Pr.</last_name>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla, Pr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorella Melillo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Sassari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Fozza</last_name>
    </contact>
    <investigator>
      <last_name>Claudio Fozza</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco Longu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano D'Ardia</last_name>
    </contact>
    <investigator>
      <last_name>Barbara Amato</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano D'Ardia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>March 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Quality of life</keyword>
  <keyword>acute promyelocytic leukemia</keyword>
  <keyword>ATO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

